Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 4/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24122539 | 0.82 | MAT2A (0.38) | MAT2ASLC40A1HCRTR1HCRTR2TRPV1 | |
| SCHEMBL30489832 | 0.82 | MAT2A (0.38) | MAT2ASLC40A1HCRTR1HCRTR2TRPV1 | |
| SCHEMBL24596343 | 0.82 | SYK (0.37) | MAT2ASLC40A1IGF1RSYKGRM5 | |
| SCHEMBL24596367 | 0.81 | DHODH (0.47) | MAT2AHCRTR1HCRTR2TRPV1SYK | |
| SCHEMBL24596302 | 0.80 | MAT2A (0.39) | MAT2ASLC40A1SYKGRM5TAS2R14 | |
| SCHEMBL26631683 | 0.77 | GRM5 (0.41) | SLC40A1HCRTR1HCRTR2SYKGRM5 | |
| SCHEMBL24596212 | 0.77 | ULK1 (0.44) | MAT2ASLC40A1SYKGRM5 | |
| SCHEMBL24596390 | 0.73 | LMNA (0.45) | IGF1RTAS2R14 | |
| SCHEMBL24596297 | 0.73 | EPHX2 (0.47) | TAS2R14 | |
| SCHEMBL24596277 | 0.73 | GRM5 (0.41) | SYKGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | MAT2A 1/4885SLC40A1 3158/4885HCRTR1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.